Gloria
González Aseguinolaza
Investigadora Senior
Publicacions en què col·labora amb Gloria González Aseguinolaza (24)
2024
2022
-
High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease
Molecular Therapy - Methods and Clinical Development, Vol. 26, pp. 98-106
2021
-
Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis
Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221
-
Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations
Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602
2019
-
Danio rerio as model organism for adenoviral vector evaluation
Genes, Vol. 10, Núm. 12
-
Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice
Hepatology, Vol. 70, Núm. 1, pp. 108-126
2018
2017
-
Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis
Human Gene Therapy Clinical Development, Vol. 28, Núm. 2, pp. 68-73
2016
-
A versatile vector for in vivo monitoring of type I interferon induction and signaling
PLoS ONE, Vol. 11, Núm. 3
-
Long-term metabolic correction of Wilson's disease in a murine model by gene therapy
Journal of Hepatology, Vol. 64, Núm. 2, pp. 419-426
2015
-
Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model
Molecular Cancer, Vol. 14, Núm. 1
-
Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver
Liver International, Vol. 35, Núm. 4, pp. 1274-1289
2013
-
Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives
Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841
2012
-
Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B
Hepatology, Vol. 56, Núm. 2, pp. 474-483
2011
-
Gene therapy of liver cancer: An update
Journal Africain du Cancer, Vol. 3, Núm. 3, pp. 180-192
-
Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice
Gut, Vol. 60, Núm. 3, pp. 341-349
-
Self-inactivating helper virus for the production of high-capacity adenoviral vectors
Gene Therapy, Vol. 18, Núm. 11, pp. 1025-1033
-
Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice
Molecular Therapy, Vol. 19, Núm. 2, pp. 243-250
2010
-
Gene therapy for HCV/HBV-induced hepatocellular carcinoma
Current Opinion in Investigational Drugs, Vol. 11, Núm. 12, pp. 1368-1377